Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD)
Abstract Background Oculopharyngeal muscular dystrophy (OPMD) is a late‐onset muscle disease affecting one per 80 000 of the general population characterized by profound dysphagia and ptosis, and limb weakness at later stages. Affected muscles are characterized by increased fibrosis and atrophy. Myo...
Saved in:
Main Authors: | Pradeep Harish (Author), Alberto Malerba (Author), Ngoc Lu‐Nguyen (Author), Leysa Forrest (Author), Ornella Cappellari (Author), Fanny Roth (Author), Capucine Trollet (Author), Linda Popplewell (Author), George Dickson (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2019-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy
by: Vanessa Strings-Ufombah, et al.
Published: (2021) -
Different outcomes of endurance and resistance exercise in skeletal muscles of Oculopharyngeal muscular dystrophy
by: Alexis Boulinguiez, et al.
Published: (2024) -
RNA-Based Therapy Utilizing Oculopharyngeal Muscular Dystrophy Transcript Knockdown and Replacement
by: Aida Abu-Baker, et al.
Published: (2019) -
Systemic Antisense Therapeutics for Dystrophin and Myostatin Exon Splice Modulation Improve Muscle Pathology of Adult mdx Mice
by: Ngoc Lu-Nguyen, et al.
Published: (2017) -
Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
by: Haiyan Zhou, et al.
Published: (2020)